3UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J]. Lancet, 1998,352(9131) :837-853.
4Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901)in comparison with those of NPH insulin and placebo 7j], Diabetes Care, 2000,23 ( 5 ) : 644-649.
5Ashwell S G, Home P D. Insulin glargine: the first clinically useful extended-action insulin analogue [J]. Expert Opin Pharmacother, 2001,2( 11 ) : 1891-1902.
6Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901 ) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens, U.S. Insulin Glargine (HOE 901 ) Type 1 Diabetes Investigator Group [J]. Diabetes Care, 2000,23 (8) : 1137-1142.
7Owens D R. Repaglinide prandial glucose regulator: a new class of oral antidiabetic drugs [J]. Diabet Med, 1998, 15 ( Suppl 4) : S28-S36.
8Jovanovic L, Dailey G 3rd, Huang W C, et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study [J]. J Clin Pharmacol, 2000,40( 1 ) :49-57.
9Li YB, Xu W, Liao ZH, et al.Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function.Diabetes Care, 2004, 27:2597-2602.
